JAK Inhibitors and S1P Modulators for IBD

Table of Contents

  1. Why Pills Now Matter — Small Molecules vs Biologics
  2. JAK Inhibitors: How They Work
  3. Tofacitinib (Xeljanz) and the OCTAVE Trials
  4. Upadacitinib (Rinvoq) and the U-ACHIEVE/U-ACCOMPLISH Program
  5. Filgotinib — Approved Abroad, Not in the U.S.
  6. JAK Black-Box Warnings — MACE, VTE, Malignancy
  7. Cardiovascular Screening Before Starting
  8. S1P Receptor Modulators: How They Work
  9. Ozanimod (Zeposia) and True North
  10. Etrasimod (Velsipity) and ELEVATE UC
  11. S1P Cardiac Monitoring and Lymphocyte Drop
  12. Where Oral Agents Fit in Your Treatment Plan
  13. Pregnancy and Breastfeeding
  14. Cost Realities and Insurance
  15. Practical Questions to Ask Your GI
  16. Key Research Papers
  17. Research Papers
  18. Connections

Why Pills Now Matter — Small Molecules vs Biologics

For twenty years, advanced IBD therapy meant injections or infusions. TNF inhibitors (infliximab, adalimumab), IL-23 inhibitors (ustekinumab, risankizumab), and integrin inhibitors (vedolizumab) are all biologics — large, engineered antibody proteins that must be delivered under the skin or into a vein because your stomach would digest them. If you want the science on those agents, see the biologics article.

JAK inhibitors and S1P receptor modulators are different. They are small-molecule drugs you swallow once or twice a day. No injections, no infusion chairs, no needles. A small molecule is exactly what it sounds like — a compact chemical (hundreds of daltons, not the 150,000 of a monoclonal antibody) that survives the gut, crosses cell membranes, and blocks a specific intracellular target.

The trade-offs are real. Biologics hit one precise target outside the cell; small molecules hit pathways inside the cell and tend to have broader downstream effects. That is why the FDA has placed boxed warnings on the JAK class and why cardiac monitoring is required for some S1P drugs. For many patients, though, the convenience and speed of response make these agents life-changing — especially when biologics have failed, when needles are a dealbreaker, or when disease has to be controlled fast.

JAK Inhibitors: How They Work

JAK stands for Janus kinase. Inside your immune cells, JAKs sit under the receptors that inflammatory cytokines dock onto. When a cytokine like IL-6, IL-2, IL-15, or interferon-gamma binds its receptor, the JAK enzyme gets switched on and phosphorylates a family of messenger proteins called STATs. The STATs march into the nucleus and turn on inflammatory genes. Block JAK, and you mute dozens of cytokine signals at once.

There are four JAKs: JAK1, JAK2, JAK3, and TYK2. Each pairs with specific receptors. The IBD-relevant drugs try to hit JAK1 preferentially — because hitting JAK2 too hard interferes with red-blood-cell production (causing anemia) and hitting JAK3 too hard suppresses immune development. Newer JAK inhibitors are more selective for JAK1, which is why upadacitinib and filgotinib tend to have cleaner side-effect profiles than older, less selective tofacitinib.

Because JAK inhibitors are pills, they kick in fast. Clinical improvement is often visible within 2–3 days — unusual in a field where biologics take weeks. That makes JAKs attractive when a UC flare is closing in on surgery and time matters.

Tofacitinib (Xeljanz) and the OCTAVE Trials

Tofacitinib was the first JAK inhibitor approved for ulcerative colitis (FDA, May 2018). It blocks JAK1 and JAK3 roughly equally. The approval rested on the OCTAVE trial program — three large randomized studies published by Sandborn and colleagues in the New England Journal of Medicine in 2017.

The dosing matters. Standard induction is 10 mg twice daily for 8 weeks, then step down to 5 mg twice daily for maintenance. Patients who do not fully respond can stay on 10 mg twice daily, but the FDA now recommends using the lowest effective dose because of the cardiovascular and thrombosis signal discussed below.

Tofacitinib is approved for UC only, not Crohn's disease. Early Crohn's trials did not hit endpoints, and the drug never received that indication.

Upadacitinib (Rinvoq) and the U-ACHIEVE/U-ACCOMPLISH Program

Upadacitinib is a selective JAK1 inhibitor, FDA-approved for ulcerative colitis (March 2022) and Crohn's disease (May 2023). The UC data come from the twin U-ACHIEVE and U-ACCOMPLISH induction trials plus U-ACHIEVE Maintenance; the Crohn's data come from U-EXCEL, U-EXCEED, and U-ENDURE.

Upadacitinib's JAK1 selectivity means fewer hematologic side effects than tofacitinib, but the same class warnings still apply. It is the only JAK inhibitor currently approved for both UC and Crohn's, which is a real advantage for patients whose diagnosis shifts or whose disease straddles the line. For a refresher on those differences, see the Crohn's vs UC article.

Filgotinib — Approved Abroad, Not in the U.S.

Filgotinib is another selective JAK1 inhibitor, developed by Galapagos and Gilead. The SELECTION trial showed meaningful benefit in UC — induction remission of 26% with 200 mg daily vs 15% on placebo, and maintenance remission around 37% at one year.

The European Medicines Agency approved filgotinib for UC in 2021. In the United States, however, the FDA declined approval because of concerns about testicular toxicity seen in animal studies at high doses. Clinically, the MANTA safety study did not confirm those concerns in humans, but the regulatory path stalled and Gilead returned U.S. rights to Galapagos. As of 2026, U.S. patients cannot access filgotinib for IBD; European and UK patients can.

JAK Black-Box Warnings — MACE, VTE, Malignancy

Every JAK inhibitor used in IBD carries an FDA boxed warning — the most serious regulatory warning available. The warning was added in 2021 after the ORAL Surveillance trial of tofacitinib in rheumatoid arthritis showed excess events compared with TNF inhibitors. That trial was not in IBD, but the FDA applied the warning across the whole JAK class:

Context matters. The ORAL Surveillance population was older RA patients with baseline cardiovascular disease — not the typical UC patient. IBD-specific cohorts have so far shown milder signals, and many gastroenterologists argue the JAK boxed warning overestimates risk for the average IBD patient under 50 with no smoking history. Still, the warning is there, and your doctor is required to discuss it with you.

Cardiovascular Screening Before Starting

Most gastroenterologists now run a short checklist before starting any JAK inhibitor:

S1P Receptor Modulators: How They Work

S1P stands for sphingosine-1-phosphate, a lipid molecule your body uses to control where immune cells go. Specifically, S1P acts on receptors on the surface of lymphocytes that tell them when to leave lymph nodes and enter the bloodstream. If you block one of those receptors — particularly S1P1 — the lymphocytes get trapped in their home lymph nodes and cannot reach the inflamed colon.

S1P modulators are essentially functional antagonists. They bind, trigger internalization of the S1P1 receptor, and leave the lymphocyte blind to its own exit signal. The practical effect is a targeted, reversible drop in circulating lymphocytes (usually 50–70% from baseline), with fewer disease-relevant T and B cells reaching gut tissue.

The concept is not new. The multiple sclerosis drug fingolimod pioneered the class. IBD S1P modulators are more selective, focusing on S1P1 and S1P5 while sparing S1P2, S1P3, and S1P4 — which reduces the cardiac conduction and retinal side effects that limited fingolimod.

Ozanimod (Zeposia) and True North

Ozanimod is an S1P1 and S1P5 modulator, FDA-approved for moderate-to-severe UC (May 2021). The pivotal data come from the True North trial published by Sandborn and colleagues in NEJM in 2021.

Ozanimod uses a 7-day dose-titration pack — 0.23 mg days 1–4, 0.46 mg days 5–7, then 0.92 mg from day 8 onward. This slow ramp is designed to blunt the first-dose drop in heart rate. Do not skip it; restarting after a missed dose longer than 14 days requires starting the titration pack over.

Ozanimod is metabolized partly by monoamine oxidase. That triggers a real drug interaction warning — MAO inhibitors are contraindicated, and patients on certain antidepressants (especially older MAOIs for depression or Parkinson's drugs like selegiline) cannot take ozanimod without a careful washout.

Etrasimod (Velsipity) and ELEVATE UC

Etrasimod is a newer, once-daily S1P1, S1P4, and S1P5 modulator, FDA-approved for moderate-to-severe UC (October 2023). The approval was based on the ELEVATE UC 52 and ELEVATE UC 12 trials published by Sandborn and colleagues in The Lancet in 2023.

Etrasimod's key practical advantage is that it does not require a titration pack. You start at the full 2 mg daily dose. The half-life and pharmacology still produce a transient dip in heart rate after the first dose, so a baseline ECG is required, but the whole initiation process is simpler than ozanimod.

Etrasimod is not metabolized through MAO, so the antidepressant interaction profile is cleaner.

S1P Cardiac Monitoring and Lymphocyte Drop

Both S1P drugs require baseline workup because the S1P1 receptor lives on cardiac tissue as well as lymphocytes. Before starting:

Skin checks are also recommended, with a baseline dermatology exam and yearly follow-up. Basal cell and squamous cell skin cancer rates are slightly elevated over years on S1P modulators.

Where Oral Agents Fit in Your Treatment Plan

Ten years ago, UC and Crohn's treatment went 5-ASA, steroids, immunomodulator, biologic, surgery. JAK inhibitors and S1P modulators have scrambled that sequence. The current American Gastroenterological Association (AGA) and ACG guidance is pragmatic: in moderate-to-severe UC, you can reasonably start with a TNF inhibitor, an IL-23 inhibitor, vedolizumab, ozanimod, etrasimod, or upadacitinib. The best first choice depends on disease severity, speed needed, age, smoking history, comorbidities, and insurance.

Typical scenarios where oral small molecules make sense:

What these oral agents are not usually first-line for: fistulizing perianal Crohn's (TNF inhibitors still own this), severe extensive pan-ileal Crohn's with stricture, or any patient with a fresh history of blood clots, recent heart attack, active cancer, or uncontrolled infection.

Pregnancy and Breastfeeding

This is where JAK inhibitors and S1P modulators differ sharply from TNF biologics. Anti-TNF agents like infliximab and adalimumab have two decades of pregnancy data and are generally considered safe to continue through pregnancy. Vedolizumab and ustekinumab have solid data too.

The oral small molecules are different. Both classes cross the placenta and both have signals in animal reproductive studies:

If you are planning pregnancy or there is any chance you could become pregnant, talk to your GI before starting. Many patients switch to a biologic pre-conception, deliver, breastfeed, and return to the small molecule later. Others stay on biologics long-term specifically to preserve pregnancy options.

Cost Realities and Insurance

Sticker prices for all four drugs are high — roughly $5,000 to $7,000 per month without insurance, or $60,000 to $85,000 per year. Almost no one actually pays this. The real question is what your insurance will cover, what the copay looks like, and whether the manufacturer's assistance program can bridge the rest.

Practical Questions to Ask Your GI

Key Research Papers

Research Papers

For further reading, the following PubMed topic searches return current peer-reviewed work on JAK inhibitors and S1P receptor modulators in IBD:

  1. Tofacitinib in ulcerative colitis
  2. Upadacitinib in UC and Crohn's disease
  3. Filgotinib in inflammatory bowel disease
  4. JAK inhibitors and cardiovascular risk (MACE)
  5. JAK inhibitors and venous thromboembolism
  6. Ozanimod and the True North trial
  7. Etrasimod and the ELEVATE UC program
  8. S1P receptor modulators in IBD
  9. JAK inhibitors in pregnancy and IBD
  10. Positioning advanced therapies in ulcerative colitis

Connections

Back to Table of Contents